Follow
Paul de Souza
Paul de Souza
Sydney University, Western Sydney University
Verified email at sydney.edu.au
Title
Cited by
Cited by
Year
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
32132013
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ...
New England Journal of Medicine 369 (8), 722-731, 2013
20922013
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall …
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160, 2015
15542015
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
JAMA Oncology 6 (7), 1003-1010, 2020
10082020
Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized …
LS Rosen, D Gordon, NS Tchekmedyian, R Yanagihara, V Hirsh, ...
Cancer 100 (12), 2613-2621, 2004
9292004
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the …
LS Rosen, D Gordon, S Tchekmedyian, R Yanagihara, V Hirsh, ...
Journal of Clinical Oncology 21 (16), 3150-3157, 2003
9102003
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma
TE Hutson, ID Davis, JPH Machiels, PL De Souza, S Rottey, B Hong, ...
Journal of Clinical Oncology 28 (3), 475-480, 2010
3542010
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ...
European urology 66 (5), 815-825, 2014
3522014
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
JP Dutcher, P de Souza, D McDermott, RA Figlin, A Berkenblit, A Thiele, ...
Medical oncology 26, 202-209, 2009
3352009
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized …
TK Choueiri, DJ Figueroa, AP Fay, S Signoretti, Y Liu, R Gagnon, K Deen, ...
Clinical Cancer Research 21 (5), 1071-1077, 2015
2762015
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo‐controlled …
TH Diamond, J Winters, A Smith, P De Souza, JH Kersley, WJ Lynch, ...
Cancer 92 (6), 1444-1450, 2001
2152001
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer
P Fox, M Hudson, C Brown, S Lord, V Gebski, P De Souza, CK Lee
British journal of cancer 109 (1), 147-153, 2013
1892013
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
CF Xu, NX Bing, HA Ball, D Rajagopalan, CN Sternberg, TE Hutson, ...
Journal of clinical oncology 29 (18), 2557-2564, 2011
1872011
Emerging roles for phospholipase A2 enzymes in cancer
KF Scott, M Sajinovic, J Hein, S Nixdorf, P Galettis, W Liauw, P de Souza, ...
Biochimie 92 (6), 601-610, 2010
1872010
Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study
D Goldstein, BK Bennett, K Webber, F Boyle, PL De Souza, NRC Wilcken, ...
Journal of clinical oncology 30 (15), 1805-1812, 2012
1662012
Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer
W Scarano, P De Souza, MH Stenzel
Biomaterials science 3 (1), 163-174, 2015
1582015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results
MJ Morris, A Molina, EJ Small, JS De Bono, CJ Logothetis, K Fizazi, ...
Journal of Clinical Oncology 33 (12), 1356, 2015
1492015
Thiol–yne and thiol–ene “click” chemistry as a tool for a variety of platinum drug delivery carriers, from statistical copolymers to crosslinked micelles
VT Huynh, G Chen, P Souza, MH Stenzel
Biomacromolecules 12 (5), 1738-1751, 2011
1422011
Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer
AC Won, H Gurney, G Marx, P De Souza, MI Patel
BJU Int 112 (4), E250-E255, 2013
1352013
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant …
CJ Ryan, MR Smith, JS De Bono, A Molina, C Logothetis, PL De Souza, ...
Journal of Clinical Oncology 30 (15_suppl), LBA4518-LBA4518, 2012
1352012
The system can't perform the operation now. Try again later.
Articles 1–20